Glaukos Corporation (NYSE: GKOS) is a Healthcare company (Medical - Devices) with a market capitalization of $14.4B. The Maz Rating grades it against the other companies in its sector.
Glaukos Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $243.25, Glaukos Corporation trades at 20.9x sales and 20.1x book value. Over the last twelve months it generated about $688M of revenue and a net loss of $173M. It runs a gross margin of 81.1%, an operating margin of -9.2% and a net margin of -24.6%. It shows return on equity of -24.9%, return on invested capital of -7.2% and a free cash flow yield of 0.3%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 4.57. Over the past 52 weeks the share price ranged from $73.16 to $255.19, with a beta of 0.69.
Glaukos Corporation does not currently pay a dividend.
25 Wall Street analyst ratings cover the stock: 18 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Glaukos Corporation (GKOS) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.09% / 30% · Interest income / Revenue 1.18% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.09% / 33% · Receivables / Mkt Cap (36m) 1.38% / 49% · Interest income / Revenue 1.18% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.09% / 33.33% · Receivables / Mkt Cap (24m) 1.38% / 33.33% · Interest income / Revenue 1.18% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 6.55% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 32.0% / 33.33% · Receivables / Avg Assets (4Q) 14.0% / 33.33% · Interest income / Revenue 1.18% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 34.4% / 33.33% · (Cash+Recv) / Total Assets 49.7% / 33.33% · Interest income / Revenue 1.18% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Glaukos Corporation (GKOS) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Glaukos Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.18% of each dividend: Glaukos Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.